最新消息

Europe: Guidance on Post-Market Surveillance of Medical Devices and In Vitro Diagnostic Medical Devices – December 2025/January 2026

Europe: Guidance on Post-Market Surveillance of Medical Devices and In Vitro Diagnostic Medical Devices – December 2025/January 2026

  • 2026-01-30 04:29:37

The European Union has established post-market surveillance (PMS) requirements under the Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR) to ensure the continuous safety and performance of medical devices and IVDs placed on the market. This framework emphasizes proactive monitoring, data collection, and lifecycle-based compliance to promptly identify and address potential risks.

了解更多
Qualtech Webinar: Expert Insights - EU MDR Updates 2026 – February 2026

Qualtech Webinar: Expert Insights - EU MDR Updates 2026 – February 2026

  • 2026-01-20 03:48:00

Join Qualtech's free webinar "Expert Insights - EU MDR Updates 2026" on February 12, 2026, to gain practical insights and stay up to date with the most recent developments in the European Medical Device Regulation. This session will assist you and your organization to confidently navigate EU MDR requirements and prepare for the end of the transition period. Stay informed, stay compliant, and turn MDR challenges into opportunities.

了解更多
QT Activity: 2025 Updates & Forecast for European Medical Device Regulations Webinar Summary Recap – February/March 2025

QT Activity: 2025 Updates & Forecast for European Medical Device Regulations Webinar Summary Recap – February/March 2025

  • 2025-02-21 05:38:28

Qualtech hosted a webinar providing key insights into the evolving European medical device regulations. The discussion covered essential updates, including the MDR transition period extension, Article 10A supply notification requirements, the gradual rollout of EUDAMED, the implications of the European AI Act, and regulatory changes in the UK and Switzerland. Attendees gained valuable guidance on compliance strategies and proactive measures to navigate these regulatory shifts.

了解更多
Australia: Understanding the Therapeutic Goods Administration's (TGA) Recall Reforms and the Introduction of the PRAC – January/February 2025

Australia: Understanding the Therapeutic Goods Administration's (TGA) Recall Reforms and the Introduction of the PRAC – January/February 2025

  • 2025-01-22 07:36:15

The Therapeutic Goods Administration (TGA) has introduced the Procedure for Recalls, Product Alerts, and Product Corrections (PRAC) to streamline and enhance the recall processes for therapeutic goods in Australia. By reducing recall categories, simplifying procedural steps, and improving communication, the PRAC aims to foster efficiency and clarity for manufacturers and regulatory consultants. With implementation set for March 2025, stakeholders are encouraged to prepare for these reforms to ensure compliance and contribute to a safer therapeutic goods landscape.

了解更多
Australia: TGA Issues Reminder on Advertising Rules for Therapeutic Goods: Key Guidelines for Social Media Compliance – October/November 2024

Australia: TGA Issues Reminder on Advertising Rules for Therapeutic Goods: Key Guidelines for Social Media Compliance – October/November 2024

  • 2024-11-05 02:13:00

The Therapeutic Goods Administration (TGA) has issued a reminder to manufacturers and marketers to comply with advertising rules for therapeutic goods, particularly on social media, following a rise in non-compliance cases. Key rules include ensuring ads are truthful, promoting only registered goods, adhering to endorsement guidelines, avoiding unapproved uses, clearly presenting risks and health warnings, and ensuring influencer content meets regulatory standards.

了解更多